Human CD63 Full Length Protein (VLP)
分子别名(Synonym)
LAMP-3, ME491, MLA1, OMA81H, TSPAN30
表达区间及表达系统(Source)
Human CD63 Full Length Protein (VLP) (CD3-H52P6) is expressed from human 293 cells (HEK293). It contains AA Ala 2 - Met 238 (Accession # P08962).
Predicted N-terminus: Met
蛋白结构(Molecular Characterization)
Virus-like particles(VLPs) are formed by self-assembly of envelop/capsid proteins from viruses. Membrane Proteins can be constituted in-situ with VLPs produced from HEK293 cell cultures. These VLPs concentrate conformationally intact membrane proteins directly on the cell surface and produce soluble, high-concentration proteins perfect for immunization and antibody screening.

The VLPs provide the display of properly folded membrane proteins in their native cellular membrane in a compact size of 100~300 nm diameter (similar to the size of most viruses) making it optimal targets for dendritic cells in vivo and surface attachment for phage display.
制剂(Formulation)
The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).
Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
运输(Shipping)
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存储(Storage)
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product MUST be stored at -70°C or lower upon receipt;
-70°C for 12 months under sterile conditions.

背景(Background)
Functions as a cell surface receptor for TIMP1 and plays a role in the activation of cellular signaling cascades. Plays a role in the activation of ITGB1 and integrin signaling, leading to the activation of AKT, FAK/PTK2 and MAP kinases. Promotes cell survival, reorganization of the actin cytoskeleton, cell adhesion, spreading and migration, via its role in the activation of AKT and FAK/PTK2. Plays a role in VEGFA signaling via its role in regulating the internalization of KDR/VEGFR2. Plays a role in intracellular vesicular transport processes, and is required for normal trafficking of the PMEL luminal domain that is essential for the development and maturation of melanocytes. Plays a role in the adhesion of leukocytes onto endothelial cells via its role in the regulation of SELP trafficking. May play a role in mast cell degranulation in response to Ms4a2/FceRI stimulation, but not in mast cell degranulation in response to other stimuli.
关键字: CD63;CD63蛋白;CD63重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等国家的12个城市设有办公室、研发中心及生产基地。目前累计服务客户超8000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。
ACROBiosystems百普赛斯子品牌包括膜杰作、Star Staining、Aneuro、ComboX、ActiveMax、GENPower等,主要产品及服务包括蛋白、抗体、试剂盒及分析检测服务,应用于肿瘤、自身免疫疾病、心血管病、传染病、脑神经等疾病的药物筛选及优化、临床前实验及临床试验、药物生产过程及工艺控制(CMC)、诊断试剂开发及优化等研发及生产环节。
百普赛斯集团ACROBiosystems Group以加速生物药研发上市进程和服务于更好的临床应用为使命,愿通过自己的努力,从为客户带来价值开始,到为全球市场整个行业创造价值,公司不断通过更新技术、产品、服务,积极为合作伙伴赋能,来加速包括靶点药物和免疫治疗药物在内的,各种生物医药的研发上市进程和临床上更好的应用,最终为人类健康事业做出贡献。